You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Personalized anesthetic brain monitoring:Developing novel systems, sensors, and algorithms for aging, dementia, and Alzheimers disease patients

    SBC: PASCALL Systems, Incorporated            Topic: R

    PROJECT SUMMARY In the United States, nearly 100,000 patients receive general anesthesia and sedation daily to safely undergo surgical and non-surgical procedures. A high proportion of these patients are older than 65 years of age. These older patients are at higher risk of post-operative delirium and cognitive dysfunction. Many of these older patients have dementia, including mild cognitive impai ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD

    SBC: Aromha Inc            Topic: NIA

    Project Summary / Abstract Over 5.8 million Americans are currently affected by Alzheimerandapos;s disease (AD) with an economic burden estimated at andgt; $270 billion/year in 2020 that is projected to increase at least four fold over the next several decades. Accurate biomarkers have been developed that demonstrate that AD pathology is present 15 years of more prior to the onset of memory sympto ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Multi-Modality Image Data Fusion and Machine Learning Approaches for Personalized Diagnostics and Prognostics of MCI due to AD

    SBC: MS Technologies Corporation            Topic: R

    Alzheimer’s Disease (AD) is a devastating neurodegenerative disease. The greatest treatment potential lies in early stages before irreversible brain damage occurs. Early treatment requires early detection of the disease. Imaging holds great promise for capturing early signs of AD. This capability can be substantially strengthened by integrating neuroimages of different modalities that characteri ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Attend BIO conference to meet with potential commercialization partners for ultra-fast MRI technology

    SBC: WEINBERG MEDICAL PHYSICS, INC.            Topic: NINDS

    DESCRIPTION provided by applicant This application represents a competing renewal request for a Phase II STTR project in which we constructed an ultra fast gradient system for magnetic resonance imaging Operation of the novel system is based upon the principle that the nervous system is relatively insensitive to very short exposures to changing magnetic fields As a result we are showing in ...

    STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Bio-Effects of Ultra-High MRI Gradient Slew Rates

    SBC: WEINBERG MEDICAL PHYSICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): This application represents a competing renewal request for a Phase II STTR project, in which we constructed an ultra-fast gradient system for magnetic resonance imaging. Operation of the novel system is based upon theprinciple that the nervous system is relatively insensitive to very short exposures to changing magnetic fields. As a result, we are showing in c ...

    STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Lentiviral-MGMT gene transfer into hematopoietic stem cells

    SBC: LENTIGEN CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): Therapeutic stem cell gene transfer relies on long-term gene expression achieved by integration of new DNA into the cellular genome. Current clinical trials featuring oncoretroviruses have encountered a number of roadblocks that include low levels of gene transfer, poor expression, and a recognized preferential insertion near promoter regions that increases the ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis

    SBC: Aridis Pharmaceuticals, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Over the past two decades, the number of new antimicrobials being developed has experienced a greater than 60% decline, while the number of antibiotic resistant microorganisms has been steadily increasing. Only one newantibacterial drug with a novel mechanism of action (linezolid) has been introduced during this period making the long term outlook for sustained ...

    STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  8. Preclinical Testing of a Novel Flow Diverting Stent for Treating Intracranial Aneurysms

    SBC: NeuroSigma, Inc.            Topic: 101

    DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens

    SBC: SILVER LAKE RESEARCH CORPORATION            Topic: NIAID

    PROJECT SUMMARY ABSTRACT This proposal describes Phase II of the development of a rapid immunoassay test kit for the determination oflactam antibiotic resistanceto be used as a point of care diagnostic test for urinary tract infectionsTodayantibiotics for UTI are prescribed empiricallywith no diagnostics available to clinicians to avoid treating resistant infections with the very drug to which the ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Project Summary Bacillus anthracis (Ba) is a Gram-positive spore forming bacterium that is listed as an agent of highest concern (Category A) by NIAID and CDC. Ba is easy to grow, and its spores can be formulated into highly stable powder form and disseminated as aerosol or used to contaminate food or water. In 2001, letters laced with powdered anthrax spores were mailed to several US politicians. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government